GLS and non-small cell lung carcinoma: Glutamine metabolism in Osimertinib‐resistant NSCLC is complex and multifaceted; therefore, a comprehensive inhibition strategy targeting multiple nodes, such as ASCT2 and GLS1, or employing broad‐spectrum inhibition is essential to prevent rapid metabolic rewiring.